COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma (HD-MCL2003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00946374
Recruitment Status : Unknown
Verified July 2009 by Heidelberg University.
Recruitment status was:  Recruiting
First Posted : July 27, 2009
Last Update Posted : July 27, 2009
Information provided by:
Heidelberg University

Brief Summary:
The purpose of this study is to improve the overall survival of Mantle-Cell-Lymphoma (MCL) by a new concept of treatment with primary curative intention consisting of six courses of immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (SCT) and HLA-identical allogenic SCT after a dose-reduced conditioning regimen of total body irradiation (TBI) with 2 Gy and Fludarabine in younger patients with primary Mantle-Cell-Lymphoma

Condition or disease Intervention/treatment Phase
Mantle-Cell Lymphoma Drug: Immunochemotherapy Drug: High-dose BEAM plus autologous SCT Other: HLA-identical allogenic SCT Phase 2

Detailed Description:
With a median overall survival of approximately 3 years, MCL has the poorest prognosis of all NHL entities. No potentially curative therapy has been established yet as even more intensive therapies including high-dose chemotherapy plus autologous SCT show only moderate improvement of the prognosis of MCL. Allogenic SCT seems to have an immunological mechanism of action in NHL, which is commonly known as Graft-versus-Lymphoma effect. This trial´s purpose is to improve the overall survival in patients younger than 55 years with primary MCL by sequentially combining autologous SCT and allogenic SCT after the application of 6 courses of immunochemotherapy and high-dose chemotherapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Phase II Trial on R-CHOP Followed by High-dose BEAM and Autologous SCT and HLA-identical Allogenic SCT After Dose-reduced Conditioning in Patients Age < 55 Years With Primary Mantle-Cell-Lymphoma
Study Start Date : July 2004
Estimated Primary Completion Date : December 2010
Estimated Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Intervention Details:
  • Drug: Immunochemotherapy
    R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
    Other Names:
    • R-CHOP
    • CHOP
    • MabThera®
    • Endoxan®
    • Cytoxan®
    • Neosar®
    • Procytox®
    • Revimmune®
    • Oncovin®
    • Adriamycin®
    • Decortin®
    • Corticosteroid
    • Steroid
    • Cellcristin®
    • CAELYX®
    • Adriblastin®
    • Doxo-Cell®
  • Drug: High-dose BEAM plus autologous SCT
    High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( > 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
    Other Names:
    • BEAM
    • High-dose BEAM
    • ABSCT
    • ASCT
    • BCNU
    • Crmubris®
    • ARA-C
    • Eposin®
    • Etopophos®
    • ETO CELL®
    • Vepesid®
    • VP-16®
    • Alkeran®
  • Other: HLA-identical allogenic SCT
    Fludarabine 30 mg/m², iv, day -4 to day -2; Cyclosporin A 2 x 3mg/kg, iv, day -1 to day 0 plus total body irradiation with 2 Gy, day 0 followed by allogenic stem cell transplantation immediately after Radiation.
    Other Names:
    • Sibling donor
    • Unrelated donor
    • HLA-identical
    • Conditioning regimen
    • Fludara®
    • Sandimmune®
    • Fludarabinphosphat
    • Neoflubin®
    • TBI
    • Ciclral®

Primary Outcome Measures :
  1. Efficacy: ORR, OS, EFS [ Time Frame: during treatment and on day 720 after allogenic SCT ]

Secondary Outcome Measures :
  1. Toxicity according to WHO-Grading [ Time Frame: During treatment and until follow-up ]
  2. GvL-effect after allogenic SCT [ Time Frame: Allogenic SCT until day 720 after transplantation ]
  3. Comparison of OS between patients completing the protocol and patients not receiving allogenic SCT [ Time Frame: First diagnosis of MCL until day 720 after transplantation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. First diagnosis of Mantle-Cell-Lymphoma without any previous therapies except for pre-phase treatment consisting of steroids
  2. Age 18 to 55 years
  3. Confirmed CD20-expression on lymphocytes
  4. Effective methods of contraception and negative pregnancy test
  5. Sufficient compliance
  6. Written patient´s informed consent

Exclusion Criteria:

  1. Manifest cardiac insufficiency, not compensated
  2. Congestive Cardiomyopathy
  3. Chronic pulmonary disease including hypoxemia
  4. Severe hypertension, not condensable with drugs
  5. Severe diabetes mellitus not condensable with drugs
  6. Renal Insufficiency ( serum creatinin > 2,0 mg/dl, other than Lymphoma related)
  7. Liver impairment ( Transaminases value more than 3 x upper normal value or Bilirubin > 2,0 mg/dl, other than Lymphoma related)
  8. HIV-Infection
  9. Active Hepatitis B-Infection if continuous virostatic treatment is not possible
  10. Active Hepatitis C-Infection
  11. Clinical signs of cerebrovascular insufficiency or cerebral damages
  12. Pregnancy, lactation or inadequate contraception in women of childbearing age
  13. Severe psychiatric disorders
  14. Transplantation in the past

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00946374

Layout table for location contacts
Contact: Markus Munder, M. D. 0049 6221 56 ext 32370

Layout table for location information
University Hospital Recruiting
Heidelberg, Germany, 69120
Contact: Markus Munder, MD         
Sponsors and Collaborators
Heidelberg University
Layout table for investigator information
Principal Investigator: Anthony D. Ho, Ph.D., Prof. Director of Department
Additional Information:
Layout table for additonal information
Responsible Party: Prof. Dr. med. A. D. Ho, University of Heidelberg Identifier: NCT00946374    
Other Study ID Numbers: L-149/2003
BfArM: A-7140-00-37/4021157
First Posted: July 27, 2009    Key Record Dates
Last Update Posted: July 27, 2009
Last Verified: July 2009
Keywords provided by Heidelberg University:
Non Hodgkin´s Lymphoma
High-dose chemotherapy
Autologous stem cell transplantation
Reduced conditioning regimen
Unrelated donor
Sibling donor
Total Body Irradiation
Allogenic stem cell transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Etoposide phosphate
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Immunosuppressive Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents